Sei Investments Co. Purchases 7,295 Shares of Solventum Co. (NYSE:SOLV)

Sei Investments Co. increased its stake in shares of Solventum Co. (NYSE:SOLV) by 24.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,638 shares of the company’s stock after buying an additional 7,295 shares during the period. Sei Investments Co.’s holdings in Solventum were worth $2,487,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Modus Advisors LLC acquired a new stake in shares of Solventum during the 4th quarter worth approximately $25,000. Stonebridge Financial Group LLC bought a new stake in Solventum in the 4th quarter valued at $26,000. Crews Bank & Trust acquired a new position in shares of Solventum during the fourth quarter worth about $32,000. Synergy Asset Management LLC acquired a new position in Solventum during the 4th quarter worth approximately $35,000. Finally, Spire Wealth Management bought a new position in Solventum in the fourth quarter valued at $37,000.

Solventum Stock Down 5.7 %

SOLV stock opened at $66.22 on Friday. The company’s 50 day moving average is $75.42 and its 200 day moving average is $71.95. The stock has a market cap of $11.45 billion and a price-to-earnings ratio of 24.08. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a report on Friday, February 28th. Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Piper Sandler raised their target price on Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. The Goldman Sachs Group increased their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Finally, Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.